Titus Gylvin

MD, PhD

General Manager
Roche Oy
 Roche is the world’s largest
biotech company
Roche’s combined strenghts in pharmaceuticals and diagnostics
have made it the leader in personalized healthcare.
Roche has brought 14 biopharmaceuticals to the market
and majority of its new molecules in development are based on
biotechnology.

www.roche.com
Roche in Finland
Roche has operated in Finland since 1982

Local decision making power due to

decentralized global organization model

Employees
90 Roche Oy
75 Roche Diagnostics Oy

Ca. 30 clinical trials

in Finland (01/2016)
Focus areas of Roche
Oncology
Rheumatology
Neuroscience
Respiratory
Immunology and infections
Ophthalmology
 A pioneer in cancer treatment

We have developed medicines for breast cancer, skin cancer,

colorectal cancer, ovarian cancer, lung cancer and to many
other cancers.

Out of all new Roche molecules in development about half are

studied for cancer treatments.

We are studying more than 20 investigational cancer

immunotherapy medicines, nine of which are in clinical trials.

www.roche.com
 Roche invests to research and
development more than any other
pharmaceutical company
 Roche annual investment to R&D
is four times the spending on
prescription medicines in Finland

Roche R&D investment in 2015

8,6*
Billion euros (globally)
Spending on
prescription
medicines in Finland
(IMS)

2,0
Billion euros

Roche annual report 2015

Currency exhange 31.12.2015 FI/ROCH/1601/0007
 Roche has strong pipeline

New molecular New

entities indications

70
Phase I-IIIb
63
Phase I-IIIb

In the next three years launches for up

to eight new medicines planned

Situation 28.1.2016 Roche reporting centre, Full year 2015 presentation,

www.roche.com Roche annual report 2015
33 % of our research 35 % of total
pipeline comes from partnered pharmaceutical sales from partnered
products and in-licensed products (CHF 12 bn
in 2014)

190 partnerships
Top 3
currently managed around
in BCG research surveys 2008- 2014
the world
 45
4 R&D collaborations

acquistions

61 2014-2015
Total new agreements 10,7
in 2015 billion euros on acquistions

4
product transactions
San Francisco Boston Basel
Tokyo
New York Shanghai
Academic collaboration around the world

Harvard
MIT
50 Karolinska Insititute
universities
Universities in Basel

Zürich

Hebrew University
Roche partnerships in Finland

Helsinki University & HUS

TAYS & FinnMedi

Auria Biobank
When evaluating partnership prospects we consider

Cultural fit

Focus on our main disease areas

Potential to revolutionise the standard of
care

Potential to be first in class or best in class

Opportunity of the new technology

 How to find us
http://www.roche.com/partnering/get_in_touch_with_us/partnering_contact_us.htm
FI/ROCH/1601/000